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many cancer types. State-of-the-art radiation treatment 
planning and delivery is fully individualized based on 
anatomical imaging, precise space-resoluted radiation dose 
models, tumor control probability- vs. normal tissue 
complication-models and clinical parameters. These advances 
in personalized radiation oncology can mainly be attributed 
to the revolutionary progress in high-precision radiation 
delivery and planning technology during the past decades and 
have been rapidly translated into clinical practice. In parallel 
radiobiological knowledge has significantly improved during 
the past decades by e.g. unravelling radiobiological 
mechanisms of radioresistance of tumors and volume-dose 
relationships for a host of radiation induced effects in normal 
tissues. This research translated into more efficient radiation 
schedules on a population base and to NTCP parameters 
clinically used for treatment planning in individual patients. 
While several bioassays, including SF2 and plating efficiency 
determined in human tumor biopsies, provided proof-of-
concept of radiobiological mechanisms, these early assays 
could not be applied to tailor a treatment strategy for an 
individual patient. Revolutionary advances in biotechnology 
and tumor biology allow to profile tumors rapidly, thereby 
providing information on resistance parameters (e.g. hypoxia, 
stem cell density, radiosensitivity) which can be rationally 
tested for their prognostic and predictive power for 
radiotherapy. The same applies for biological imaging which 
may be of particular relevance for advancing biology-driven 
individualization of radiation oncology. One uniqueness for 
the development of personalized radiation oncology is that 
already a broad biological stratification of patients can 
substantially enhance individualization as this information 
adds to the fully anatomically-personalized dose-distributions 
achieved today. Therefore biomarker driven high precision 
radiotherapy is in pole position to create a show-case for 
personalized oncology at large.  
This lecture will review preclinical and clinical-translational 
examples of potential strategies to further personalize 
radiation oncology by inclusion of biomarkers. 
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The advent of genomics has revolutionized our understanding 
of breast cancer as several biologically and molecularly 
distinct diseases. New molecular techniques generate data 
about the intrinsic characteristics of a tumour, thereby 
providing useful diagnostic, prognostic and predictive 
information. Commercially available tests have begun to 
fundamentally change the clinicopathological paradigm of 
selecting patients for adjuvant systemic therapies in early 
breast cancer. Several recently published radiosensitivity 
gene expression signatures aim to predict response to 
adjuvant radiotherapy. The ultimate aim of biomarker 
research is to individualise therapies in order to maximise 
tumour response whilst minimizing overtreatment and 
toxicities. This talk will review the strengths and limitations 
of currently available breast cancer-specific molecular tests 
with a view to response prediction. 
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Clinical reports of limited and treatable cancer metastases, a 
disease state that exists in a transitional zone between 
localized and widespread systemic disease, have been 
reported and are now termed oligometastasis. SBRT 
treatment of oligometastases has shown promising local 
control rates (65-97%), and a good toxicity profile (<5% of 
serious adverse events) because the delivered doses are 
ablative and spatially limited. 1, 2 However, most of these 
patients usually recur at distant sites, outside of the 
irradiated area, with a median time to progression of 4 to 6 
months, indicative of occult metastatic deposits at the time 
of treatment. Thus, although SBRT is effective in definitively 
ablating most treated lesions, distant tumors progress 
highlighting the need for better systemic therapies.3  
Immunotherapy has emerged as an independent therapeutic 
modality that can result in objective – even complete – 
responses and significant amelioration of overall survival in 
patients with advanced metastatic tumors. There is an 
emerging opportunity for combining immune therapy 
together with ablative SBRT for oligometastatic patients, 
with the final aim of increasing T cell infiltration into the 
tumor.  
In situ vaccination during lethal RT of few metastases  
Lethal (high) doses of radiation can induce immunogenic 
death in cancer cells, i.e. irradiated cancer cells can trigger 
an antitumor immune response. RT can upregulate the 
necessary “eat-me” signals that promote the uptake of dying 
tumor cells by dendritic cells (DCs) and macrophages4. 
However, a systemic immune response against distant lesions 
(the so-called abscopal effect) is rarely seen. Given the 
beneficial but limited immune modulatory effects of SBRT, 
combination of SBRT with simultaneous activation of other 
immune-pathways could lead to antigen-specific adaptive 
immunity, a phenomenon called “in situ vaccination”.5An 
abscopal effect has been observed when RT was combined 
with immunotherapy and has been proven to be T-cell 
mediated. 6-8 A recent report of patients with melanoma and 
renal cell carcinoma treated with SBRT (20 Gy), in 
combination with IL-2 showed higher than expected abscopal 
responses.9 In a phase I trial combination 8 Gy in 2-3 fractions 
with ipilimumab partial responses were observed in 18% of 
the patients. When dual checkpoint blockade with both anti-
CTLA4 and anti-PD-1 combined with radiation was tested in a 
B16 melanoma model improved responses and abscopal 
effects were observed. Even in the presence of dual 
checkpoint blockade, omission of radiation resulted in high 
rates of relapse.10  
The combination of lethal SBRT to few tumor deposits in 
combination with different immunotherapy strategies triggers 
antitumor immunity. However, the key question that needs 
to be answered is which are the best combinatorial 
strategies, the best timing to combine them and how to 
increase effective homing of antitumor T cells to the 
remaining tumor deposits. Modifying the tumor 
microenvironment in these residual tumors is therefore of 
major importance to improve therapeutic outcome and 
finally cure.  
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Stereotactic body radiotherapy (SBRT) is attracting 
substantial interest as a treatment option for selected 
patients with metastatic disease. It is reasonable to take a 
step back and take a look at where the field is now and what 
we can expect from this intervention. This presentation will 
focus on a number of contemporary clinical issues, including: 
what can be expected from SBRT at various anatomical sites; 
definitions of oligo-metastatic disease and their limitations; 
defining treatment goals in metastatic disease; lessons from 
published outcome data; a pragmatic approach to decision-
making in the clinic; is radiation technology driving the 
agenda? and; gathering evidence for the future. 
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Patients with oligometastases from colo-rectal carcinoma 
(CRC) are often considered as candidates for surgical 
resection, radiofrequency ablation and SBRT and CRC often 
metastasize to the abdominal organs, especially to the liver. 
Therefore, abdominal oligo-metastases are often treated 
with SBRT. A relative large number of publications 
demonstrate outcome after SBRT for liver metastases that 
are almost as good as for lung metastases. Local control rates 
in both lung and liver are most often in the range 70-90% and 
survival rates are depending on tumor type and the selection 
of the patients. There are only few publications on SBRT of 
abdominal, non-liver oligometastases, but the few available 
publications indicate favourable local control as well for 
these patients. Most publications on SBRT for abdominal 
targets report a low risk of morbidity, but there are reports 
of relatively severe morbidity related to irradiation of the 
liver and the bowel, most often in terms of severe mucositis 
or intestinal ulceration. Treatment of abdominal targets is 
complex due to the multiple organs at risk. Treatment 
planning is based on a snapshot of the anatomy on a 
treatment planning CT-scan. 4DCT takes the intrafraction 
motion motion of the target into account, but we usually do 
not take the motion of bowel structures into account. CBCT is 
used to correct for set-up errors of the target, but organs at 
risk are less often considered. This may lead to unintended 
high doses to the organs at risk and side effects that were not 
expected from the treatment planning. 
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Recent progress has been made in oncology with new drug 
targeting immune system. Ipilimumab which targets CTLA-4 
has been the first one approved in melanoma. Another way to 
block the deleterious cascade of T-lymphocyte inhibition is to 
block an extracellular target, namely Programmed Death 
Receptor-1 (PD-1). PD-1 is a cell surface receptor expressed 
by T cells, B cells, and myeloid cells, and member of the 
CD28 family involved in T cell regulation. PD-1 pathway is 
activated by receptor binding to ligands (PD-L1 or PD-L2) and 
its physiological role is to prevent uncontrolled immune 
activation during chronic infection or inflammation. In 
cancer, activation of PD-1 pathway can suppress antitumor 
immunity. In mouse models, antibodies blocking PD-1/PD-L1 
interaction lead to tumor rejection. In clinical trials, 
targeting PD-1 pathway using human monoclonal antibody 
such as nivolumab, which blocks binding of PD-1 to PD-L1 and 
PD-L2, showed promising results in metastatic solid tumors 
with durability of objective responses, and sustained overall 
survival (Topalian and al, NEJM 2012). Phase I studies showed 
a potential better safety profile of anti-PD-1/PD-L1 agents in 
comparison with ipilimumab. Following, anti-PD-1/PD-L1 
drugs have been developed at a phenomenal speed, taking 
just three years from the first clinical trials to approval. At 
now, anti-PD-1 nivolumab and pembrolizumab are approved 
in melanoma and NSLCC... There is a strong rationale for 
using anti-PD-1/PD-L1 agents in HNSCC. Tumor-infiltrating 
lymphocytes (TILs) which are required for PD-1 blockade, and 
PD-L1 expression are present in HPV+ and HPV negative 
HNSCC. There is a correlation between infiltration by CD8 
cells and response to CRT, and between PD-L1 expression and 
survival. The high number of specific mutations observed in 
HNSCC could be a mechanism of immunogenicity. Results of 
phase I studies testing anti-PD-1/PD-L1 agents in HNSCC 
patients have been recently reported with promising results 
in terms of efficacy with prolonged responses. During ASCO 
2014 meeting, Seiwert et al. presented first results of a 
phase Ib study of pembrolizumab in recurrent/metastatic 
(R/M) HNSCC patients. Patients with ≥1% PD -L1 
immunohistochemistry expression in tumor cells or stroma 
were enrolled in the study. The anti-tumor effect was 
observed both in patients with HPV-positive and HPV-
negative tumors. The duration of these responses was 
impressive, some already lasting over one year (Seiwert TY et 
al., ASCO 2014, CSS 6011). Updated data on a expanded 
cohort have been presented at last ASCO 2015 meeting. 132 
(81 HPV+) R/M HNSCC patients were treated with 
prembrolizumab 200 mg Q3W regardless of HPV or PD-L1 
status. 78% received at least one line of chemotherapy. 
Tolerance was good (9.8% of grade 3-5 adverse events). 
Objective response rate was 25%, stable disease rate was 25% 
with long-lasting responses (Seiwert TY, et al. J Clin Oncol. 
2015;33(suppl): LBA6008). First results of a phase I study 
evaluating the safety and efficacy of an anti-PD-L1 agent, 
durvalumab (MEDI4736), have been presented at ESMO 2014 
congress (M. Fury M et al., abstr 988PD, ESMO 2014). 
MEDI4736 is a human IgG1 mAb, engineered to prevent ADCC 
activity, that blocks PD-L1 binding to PD-1 and CD-80. 50 pts 
with HNSCC, with median 3 prior treatments received median 
3 doses of MEDI4736 10 mg/kg q2w. Treatment-related 
